miR-34 – a microRNA replacement therapy is headed to the clinic
MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability a...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Research Foundation
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/ |
| id |
pubmed-3387671 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-33876712012-07-10 miR-34 – a microRNA replacement therapy is headed to the clinic Bader, Andreas G. Genetics MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. Frontiers Research Foundation 2012-07-02 /pmc/articles/PMC3387671/ /pubmed/22783274 http://dx.doi.org/10.3389/fgene.2012.00120 Text en Copyright © Bader. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Bader, Andreas G. |
| spellingShingle |
Bader, Andreas G. miR-34 – a microRNA replacement therapy is headed to the clinic |
| author_facet |
Bader, Andreas G. |
| author_sort |
Bader, Andreas G. |
| title |
miR-34 – a microRNA replacement therapy is headed to the clinic |
| title_short |
miR-34 – a microRNA replacement therapy is headed to the clinic |
| title_full |
miR-34 – a microRNA replacement therapy is headed to the clinic |
| title_fullStr |
miR-34 – a microRNA replacement therapy is headed to the clinic |
| title_full_unstemmed |
miR-34 – a microRNA replacement therapy is headed to the clinic |
| title_sort |
mir-34 – a microrna replacement therapy is headed to the clinic |
| description |
MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. |
| publisher |
Frontiers Research Foundation |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/ |
| _version_ |
1611540466660016128 |